background
broad
diagnost
respiratori
infect
molecular
assay
yet
accept
due
technic
difficulti
high
cost
object
evalu
clinic
applic
multiplex
realtim
pcr
studi
design
assay
target
influenza
viru
ifa
b
ifb
parainfluenza
piv
human
metapneumoviru
mpv
respiratori
syncyti
viru
rsv
rhinoviru
rv
enteroviru
ev
adenoviru
adv
human
coronavirus
pneumonia
ch
pneumonia
develop
run
daili
consecut
clinic
nasopharyng
swab
sampl
result
etiolog
identifi
sampl
ifa
rv
mpv
pneumonia
posit
ration
procedur
cost
could
reduc
custom
price
set
rel
low
per
sampl
conclus
streamlin
test
cost
limit
achiev
probabl
critic
implement
broad
molecular
diagnost
respiratori
infect
commun
acquir
respiratori
tract
infect
frequent
constitut
import
caus
morbid
sweden
european
countri
signific
part
infect
caus
viral
pathogen
creer
et
al
diaz
et
al
often
difficult
clinician
distinguish
viral
bacteri
aetiolog
may
result
overus
antibiot
lundborg
et
al
diagnosi
viral
respiratori
tract
infect
use
viral
cultur
antigen
detect
serolog
either
slow
insensit
applic
clinic
practic
gunson
et
al
reliabl
specif
sensit
pcr
method
yet
accept
first
choic
diagnosi
owe
high
cost
sever
agent
target
recent
multiplex
assay
detect
larg
number
viral
agent
describ
base
tradit
pcr
bellaupujol
et
al
grutek
et
al
correspond
author
tel
email
address
robinbl
teliacom
r
brittainlong
liolio
et
al
pupp
et
al
other
realtim
pcr
gunson
et
al
kuyper
et
al
templeton
et
al
watzing
et
al
pcr
combin
luminex
liquid
chip
hybrid
identif
li
et
al
develop
realtim
pcr
procedur
base
autom
specimen
extract
multiplex
amplif
rel
low
cost
primer
hydrolysi
probe
obtain
literatur
develop
laboratori
follow
agent
analys
influenza
viru
ifa
b
ifb
parainfluenza
piv
human
metapneumoviru
mpv
respiratori
syncyti
viru
rsv
rhinoviru
rv
enteroviru
ev
adenoviru
adv
human
coronavirus
addit
pneumonia
ch
pneumonia
includ
panel
nucleic
acid
l
specimen
extract
elut
volum
l
magnapur
lc
robot
see
front
matter
elsevi
bv
right
reserv
roch
molecular
system
mannheim
germani
use
total
nucleic
acid
protocol
amplifi
abi
realtim
pcr
system
appli
biosystem
foster
citi
ca
amplif
carri
l
reaction
volum
includ
l
sampl
prepar
l
onestep
rtpcr
master
mix
appli
biosystem
exchang
master
mix
invitrogen
carlsbad
ca
later
part
studi
period
improv
sensit
revers
transcript
step
c
min
follow
min
denatur
c
cycl
twostep
pcr
perform
c
c
sampl
amplifi
parallel
reaction
contain
primer
probe
specif
target
mixtur
ae
describ
tabl
multiplex
tend
hamper
perform
amplif
significantli
mani
combin
therefor
reagent
mixtur
care
evalu
combin
accept
ct
valu
multiplex
cycl
higher
detect
carri
separ
reaction
perform
evalu
use
plasmid
insert
period
octob
march
specimen
collect
patient
age
symptom
respiratori
tract
infect
admit
hospit
clinic
well
health
care
center
region
western
sweden
catchment
area
approxim
inhabit
inpati
outpati
includ
specimen
obtain
either
oropharynx
nasopharynx
rotat
swab
specimen
submit
diagnosi
virolog
laboratori
sahlgrenska
univers
hospit
specimen
analys
posit
one
ore
agent
follow
agent
detect
order
frequenc
n
posit
ifa
n
rv
n
mpv
n
rsv
n
n
ad
n
n
piv
n
ifb
n
ev
n
pneumonia
frequent
bacterium
n
wherea
ch
pneumonia
found
specimen
thirtyon
specimen
posit
two
agent
one
specimen
posit
agent
procedur
run
everi
work
day
result
sampl
arriv
morn
could
deliv
day
clinician
posit
rate
compar
previou
report
similar
studi
subject
rate
rsv
ifb
remark
low
probabl
infect
appear
extens
epidem
preced
year
target
multipl
agent
reaction
well
broad
rang
aetiolog
could
investig
run
cost
per
sampl
could
kept
low
sinc
procedur
streamlin
reason
number
sampl
arriv
laboratori
day
cost
divid
reagent
nucleic
acid
extract
reagent
realtim
pcr
personnel
laboratori
space
instrument
cost
overhead
yield
custom
price
believ
combin
low
cost
high
accuraci
prompt
result
deliveri
key
achiev
wide
clinic
use
molecular
diagnost
respiratori
infect
also
note
inclus
bacteri
agent
promot
willing
clinician
use
servic
probabl
mycoplasma
pneumonia
ch
pneumonia
infect
may
requir
antibiot
treatment
viral
detect
may
support
clinician
decis
avoid
antibiot
may
prompt
antivir
treatment
oseltamivir
influenza
patient
expos
famili
member
identifi
aetiolog
also
allow
clinician
better
inform
patient
prognosi
way
limit
spread
individu
therefor
believ
expand
use
molecular
diagnost
respiratori
infect
great
clinic
valu
cours
kept
mind
viral
agent
detect
highli
sensit
assay
might
reflect
asymptomat
infect
rather
caus
present
ill
identifi
viral
agent
exclud
concomit
bacteri
infect
extent
probabl
given
agent
constitut
aetiolog
agent
relat
ct
valu
lower
ct
valu
higher
probabl
may
also
relev
interpret
doubl
infect
studi
respiratori
infect
aetiolog
differ
patient
categori
clinic
util
similar
multiplex
assay
need
carri
